SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend will be approximately $45 million.

Read the original post:
Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share

Issued claims will protect use of a biomarker to assess response to Lomecel-B™ in patients with blood vessel dysfunction Issued claims will protect use of a biomarker to assess response to Lomecel-B™ in patients with blood vessel dysfunction

See original here:
Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels...

PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of analyses at the Women in Ophthalmology (WIO) Summer Symposium, which is taking place in Monterey, California from August 25-28, 2022.

Originally posted here:
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium

SAN CLEMENTE, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced its live and in-person participation at the 5CC World (5-Continent-Congress) that is being held from September 1-4, in Barcelona, Spain.

See the original post:
Sofwave™ to Showcase SUPERB™ (Synchronous Ultrasound Parallel Beam Technology) Live and In-Person at 5CC International Aesthetic Medical and...

BOCA RATON, Fla., Aug. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for?gastrointestinal diseases, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares. First Wave’s common stock will continue to be traded on the NASDAQ Capital Market under the symbol FWBI and will begin trading on a split-adjusted basis when the market opens on Friday, August 26, 2022, under a new CUSIP number, 33749P200.

See more here:
First Wave BioPharma, Inc. Announces Reverse Stock Split

ORLANDO, FL, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) ("Immune" or "IMUN"), a pioneering pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products that have a short and well-defined path to market, is pleased to announce it is in full compliance with OTC Markets following the filing of its 10-Q allowing removal of the delinquency flag and a return to Current Information status with the OTC Markets Group. New management, moving forward, will ensure the company continues to stay in full compliance with all OTC Markets reporting standards bringing confidence to the public.

Original post:
Immune Announces Filing of 10-Q and Removal of Delinquency Flag on OTC Markets Stock Quotes

NEWS RELEASE - REGULATED INFORMATION25 AUGUST 2022, 4:00PM EDT, 22:00 CET

See the rest here:
MDxHealth Reports Half Year 2022 Results

SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted expanded coverage for the use of Myriad’s BRACAnalysis® Diagnostic System as a companion diagnostic to identify patients with germline BRCA-mutated (gBRCAm) and HER2-negative high-risk recurrent breast cancer who may benefit from Lynparza®(olaparib).

Continued here:
Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in...

Dr. Heron brings decades of experience in executive leadership and life sciences research and development to Vaxart's Board Dr. Heron brings decades of experience in executive leadership and life sciences research and development to Vaxart's Board

Read the original post:
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors

Significant Milestones Achieved Significant Milestones Achieved

View post:
Kane Biotech Announces Second Quarter 2022 Financial Results

SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present a genetic evaluation and an analysis of cognitive function from the Company’s ongoing longitudinal natural history study of people living with classical homocystinuria (HCU), at the Society for the Study of Inborn Errors of Metabolism Annual Symposium in Freiburg, Germany, August 30 – September 2, 2022. Data exploring genomic population-based estimates of the incidence of HCU will also be presented. The Company is currently advancing a novel investigational enzyme replacement therapy, pegtibatinase, for the treatment of HCU.

See more here:
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

SOMERVILLE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that it will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Takeda Pharmaceutical Company Limited (“Takeda”). Following a review of its pipeline, Takeda informed Finch of its decision to terminate its collaboration with Finch, effective November 17, 2022, resulting in the return to Finch of worldwide rights to develop and commercialize FIN-524, FIN-525, and any other microbiome product candidates for inflammatory bowel disease (IBD). FIN-524 and FIN-525 are investigational, orally administered targeted microbiome product candidates composed of bacterial strains selected for their potential immuno-modulatory properties.

Continued here:
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD

TORONTO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA), the Canadian parent of Blueberries S.A.S. (“BBSAS”), the premier Latin American licensed cultivator and producer of medicinal cannabis and medicinal-grade cannabis extracts, (together the “Company” or "Blueberries"), is pleased to report its financial results for the quarter ended on June 30, 2022. Today, Blueberries has filed its unaudited condensed interim consolidated financial statements and related management's discussion and analysis, both of which are available on Blueberries’ profile at www.sedar.com. All amounts are expressed in Canadian dollars, unless otherwise noted.

Originally posted here:
Blueberries Medical Reports 2022 Q2 Financial Results and Provides Corporate and Operations Update

-- the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDA -- the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDA

Go here to see the original:
Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company addressing tumor recurrence through cell-based immunotherapies, today announces that it has entered into a binding agreement for a financing commitment of up to SEK 200 million (“Transaction”) with Negma Group Ltd, a Paris-based leading financial institution (“Negma”). The Company has also entered into a binding commitment letter to receive a shareholder loan up to SEK 50 million with its existing shareholder Van Herk Investments.

See the original post here:
Mendus AB: Mendus announces financing commitments totaling up to SEK 250 million with Van Herk Investments and Negma Group

REGULATED INFORMATION

Visit link:
Bone Therapeutics to host Extraordinary General Meeting on 26 September 2022

Figure 3. HSCs and restricted haematopoietic progenitors occupy distinct niches in the bone marrow

a. HSCs are found mainly adjacent to sinusoids throughout the bone marrow,,,, where endothelial cells and mesenchymal stromal cells promote HSC maintenance by producing SCF, CXCL12,,, and likely other factors. Similar cells may also promote HSC maintenance around other types of blood vessels, such as arterioles. The mesenchymal stromal cells can be identified based on their expression of Lepr-Cre, Prx1-Cre, Cxcl12-GFP, or Nestin-GFP transgene in mice and similar cells are likely to be identified by CD146 expression in humans. These perivascular stromal cells, which likely include Cxcl12-abundant Reticular (CAR) cells, are fated to form bone in vivo, express Mx-1-Cre and overlap with CD45/Ter119PDGFR +Sca-1+ stromal cells that are highly enriched for MSCs in culture. b. It is likely that other cells also contribute to this niche, likely including cells near bone surfaces in trabecular rich areas. Other cell types that regulate HSC niches include sympathetic nerves,, non-myelinating Schwann cells (which are also Nestin+), macrophages, osteoclasts, extracellular matrix ,, and calcium. Osteoblasts do not directly promote HSC maintenance but do promote the maintenance and perhaps the differentiation of certain lymphoid progenitors by secreting Cxcl12 and likely other factors,,,. Early lineage committed progenitors thus reside in an endosteal niche that is spatially and cellularly distinct from HSCs.

Read more from the original source:
The bone marrow niche for haematopoietic stem cells - PubMed

What Is a Bone Marrow Transplant?

A bone marrow transplant is a medical procedure performed to replace bone marrow that has been damaged or destroyed by disease, infection, or chemotherapy. This procedure involves transplanting blood stem cells, which travel to the bone marrow where they produce new blood cells and promote growth of new marrow.

Bone marrow is the spongy, fatty tissue inside your bones. It creates the following parts of the blood:

Bone marrow also contains immature blood-forming stem cells known as hematopoietic stem cells, or HSCs. Most cells are already differentiated and can only make copies of themselves. However, these stem cells are unspecialized, meaning they have the potential to multiply through cell division and either remain stem cells or differentiate and mature into many different kinds of blood cells. The HSC found in the bone marrow will make new blood cells throughout your lifespan.

A bone marrow transplant replaces your damaged stem cells with healthy cells. This helps your body make enough white blood cells, platelets, or red blood cells to avoid infections, bleeding disorders, or anemia.

Healthy stem cells can come from a donor, or they can come from your own body. In such cases, stem cells can be harvested, or grown, before you start chemotherapy or radiation treatment. Those healthy cells are then stored and used in transplantation.

Bone marrow transplants are performed when a persons marrow isnt healthy enough to function properly. This could be due to chronic infections, disease, or cancer treatments. Some reasons for a bone marrow transplant include:

A bone marrow transplant is considered a major medical procedure and increases your risk of experiencing:

The above symptoms are typically short-lived, but a bone marrow transplant can cause complications. Your chances of developing these complications depend on several factors, including:

Complications can be mild or very serious, and they can include:

Talk to your doctor about any concerns you may have. They can help you weigh the risks and complications against the potential benefits of this procedure.

There are two major types of bone marrow transplants. The type used will depend on the reason you need a transplant.

Autologous transplants involve the use of a persons own stem cells. They typically involve harvesting your cells before beginning a damaging therapy to cells like chemotherapy or radiation. After the treatment is done, your own cells are returned to your body.

This type of transplant isnt always available. It can only be used if you have a healthy bone marrow. However, it reduces the risk of some serious complications, including GVHD.

Allogeneic transplants involve the use of cells from a donor. The donor must be a close genetic match. Often, a compatible relative is the best choice, but genetic matches can also be found from a donor registry.

Allogeneic transplants are necessary if you have a condition that has damaged your bone marrow cells. However, they have a higher risk of certain complications, such as GVHD. Youll also probably need to be put onmedications to suppress your immune system so that your body doesnt attack the new cells. This can leave you susceptible to illness.

The success of an allogeneic transplant depends on how closely the donor cells match your own.

Prior to your transplant, youll undergo several tests to discover what type of bone marrow cells you need.

You may also undergo radiation or chemotherapy to kill off all cancer cells or marrow cells before you get the new stem cells.

Bone marrow transplants take up to a week. Therefore, you must make arrangements before your first transplant session. These can include:

During treatments, your immune system will be compromised, affecting its ability to fight infections. Therefore, youll stay in a special section of the hospital thats reserved for people receiving bone marrow transplants. This reduces your risk of being exposed to anything that could cause an infection.

Dont hesitate to bring a list of questions to ask your doctor. You can write down the answers or bring a friend to listen and take notes. Its important that you feel comfortable and confident before the procedure and that all of your questions are answered thoroughly.

Some hospitals have counselors available to talk with patients. The transplant process can be emotionally taxing. Talking to a professional can help you through this process.

When your doctor thinks youre ready, youll have the transplant. The procedure is similar to a blood transfusion.

If youre having an allogeneic transplant, bone marrow cells will be harvested from your donor a day or two before your procedure. If your own cells are being used, theyll be retrieved from the stem cell bank.

Cells are collected in two ways.

During a bone marrow harvest, cells are collected from both hipbones through a needle. Youre under anesthesia for this procedure, meaning youll be asleep and free of any pain.

During leukapheresis, a donor is given five shots to help the stem cells move from the bone marrow and into the bloodstream. Blood is then drawn through an intravenous (IV) line, and a machine separates out the white blood cells that contain stem cells.

A needle called a central venous catheter, or a port, will be installed on the upper right portion of your chest. This allows the fluid containing the new stem cells to flow directly into your heart. The stem cells then disperse throughout your body. They flow through your blood and into the bone marrow. Theyll become established there and begin to grow.

The port is left in place because the bone marrow transplant is done over several sessions for a few days. Multiple sessions give the new stem cells the best chance to integrate themselves into your body. That process is known as engraftment.

Through this port, youll also receive blood transfusions, liquids, and possibly nutrients. You may need medications to fight off infections and help the new marrow grow. This depends on how well you handle the treatments.

During this time, youll be closely monitored for any complications.

The success of a bone marrow transplant is primarily dependent on how closely the donor and recipient genetically match. Sometimes, it can be very difficult to find a good match among unrelated donors.

The state of your engraftment will be regularly monitored. Its generally complete between 10 and 28 days after the initial transplant. The first sign of engraftment is a rising white blood cell count. This shows that the transplant is starting to make new blood cells.

Typical recovery time for a bone marrow transplant is about three months. However, it may take up to a year for you to recover fully. Recovery depends on numerous factors, including:

Theres a possibility that some of the symptoms you experience after the transplant will remain with you for the rest of your life.

The rest is here:
Bone Marrow Transplant: Types, Procedure & Risks - Healthline

What Are Hematopoietic Stem Cells and Why Are They Important? Hematopietic stem cells (HSCs) are multipotent cells found in the blood and bone marrow with the ability to self-renew and differentiate into multiple cell types during bone marrow hematopoiesis. Clinicians use HSCs to replace or repopulate a patients blood as a form of regenerative medicine. Research into HSC development and aging facilitates better in vitro HSC expansion and broadens their potential for disease treatment, enhancing their clinical therapeutic effects.

How Hematopoietic Stem Cells DevelopHSCs begin their development during embryogenesis in the dorsal aortic tissue and are additionally found in the placenta, yolk sac, and fetal liver. This fetal hematopoiesis process is necessary to produce the blood cells required for tissue development while generating a pool of undifferentiated HSCs. At birth, these HSCs migrate into and populate the newly-formed bone marrow and maintain a steady state of self-renewal and differentiation.1 HSCs function by producing red blood cells, platelets, and white blood cells throughout life, maintaining their levels following bleeding and infection. HSCs generally give rise to partly differentiated but proliferative progenitors, which differentiate into mature cells. Because of this process, true HSCs are relatively rare in the human body.2

Using Hematopoietic Stem Cells for Research and TreatmentHematopoietic stem cell transplantsFor more than 60 years, hematopoietic stem cell transplants (HSCTs) have been the most common form of HSC therapy, and are a standard option for treating hematologic malignancies, immunodeficiency, and defective hematopoiesis disorders. HSCs are now derived from multiple sources, such as peripheral and cord blood and bone marrow. Before transplantation, the receiving patient must undergo severe immunosuppressive procedures to prevent rejection of the new stem cells.3

Hematopoietic stem cell isolationThe most common HSC isolation method involves removing blood cells from plasma using density gradient centrifugation followed by magnetic bead isolation using the CD34+ surface marker, a general marker for all hematopoietic progenitors. Using flow cytometry, scientists sort specific HSC cell types based on common cell surface markers.4 Clinicians then intravenously infuse these cells into the receiver patients marrow where they engraft and repopulate the blood and immune system. In blood cancers such as leukemias and lymphomas, restoration of the blood system by HSCT allows patients to receive high-dose chemotherapy treatments, ridding them of malignant cells. In patients with red blood cell conditions where continuous blood transfusions are not an option, such as thalassemia major, HSCT results in 80 percent disease-free survival.5

Hematopoietic stem cells in gene and tissue regeneration therapyBone marrow hematopoietic stem cells also differentiate into cells of other lineages, such as endothelial cells, cardiomyocytes, neural cells, and hepatocytes, in a process called transdifferentiation. Because adult stem cells are rare, understanding the mechanisms behind HSC transdifferentiation could provide an additional source of tissue-specific multipotent cells and influence future clinical methods for tissue regeneration. HSCs can also help repair injured organs by releasing regenerative cytokines and recruiting cells to the damage site.5 Some of the latest advances in HSC therapeutic research involve using methods such as CRISPR for correcting genetically-defective HSCs. These methods will allow a patient to receive their own genetically-compatible (syngeneic) HSCs. These are called allogeneic transplants and are more effective at avoiding graft-versus-host disease, a condition where transplants from a donor are rejected by the recipients body, leading to an immune response against other tissues and organs. Creating genetically-corrected induced pluripotent stem cells (iPSCs) from patient skin tissues and differentiating them into HSCs has also been an active area of research, although current methods remain costly and time-consuming.6 Further research is necessary to take advantage of these remarkable multipotent cells in disease therapies.

References

1. H.K. Mikkola, S.H. Orkin, The journey of developing hematopoietic stem cells, Development, 133(19):3733-44, 2006.

2. G.M. Crane et al., Adult haematopoietic stem cell niches, Nat Rev Immunol, 17(9):573-90, 2017.

3. S. Giralt, M.R. Bishop, Principles and overview of allogeneic hematopoietic stem cell transplantation, Cancer Treat Res, 144:1-21, 2009.

4. B. Kumar, S.S. Madabushi, Identification and isolation of mice and human hematopoietic stem cells, Methods Mol Biol, 1842:55-68, 2018.

5. J.Y. Lee, S.H. Hong, Hematopoietic stem cells and their roles in tissue regeneration, Int J Stem Cells, 13(1):1-12, 2020.

6. S. Demirci et al., Hematopoietic stem cells from pluripotent stem cells: Clinical potential, challenges, and future perspectives, Stem Cells Transl Med, 9(12):1549-57, 2020.

Follow this link:
Brush Up: Hematopoietic Stem Cells and Their Role in Development and Disease Therapy - The Scientist

Cord blood banking can treat a wide range of illnesses. This type of blood contains high concentrations of special stem cells. The stem cells collected from the umbilical cord can assist with autoimmune disorders and other diseases. The process of cord blood banking often occurs when a medical professional such as an obstetrician-gynecologist takes blood from an umbilical cord after the birth of a baby. The cord blood is then collected and processed. Cord blood banking has the potential to save lives.

Collected cord blood treats many diseases. The diseases that cord blood is known to combat range from leukemia to sickle cell anemia. The cord blood often helps improve an individuals immune system and bone marrow. The blood thats found within the umbilical cord is considered special because it treats a wide range of illnesses. Although it tends to work best for the child and mother, the blood can also assist other people if the results from testing for matches prove beneficial. Collecting cord blood remains an excellent option for parents and people with histories of certain illnesses. Cord blood collection is recommended for people interested in taking a proactive approach to potential future illnesses. As the saying goes, health is wealth.

Collecting cord blood and cord tissue is important because the stem cells they contain can transform into other human cells. Stem cells offer flexibility and adaptability that can prove useful when treating certain cancers.

The stem cells collected from cord blood offer almost 10 times the number of stem cells that can be collected using alternative types of collection. The process of collecting stem cells from a clamped umbilical cord after birth is considered an easier process than collecting stem cells from bone marrow.

Stem cells collected from cord blood are viewed as more favorable than those collected from bone marrow because the stem cells from cord blood have a lower likelihood of passing on blood-borne illnesses.

Cord blood remains a scarce resource for both research and stem cell transplants because of a low and limited supply. The amount of cord blood that can be collected remains relatively low because only so much can be collected after birth.

The blood is drawn from a clamped umbilical cord after birth and placed into a sterile bag. Cord blood is tested before it is accepted by a cord blood bank. Not every unit of cord blood meets the specified criteria. For example, some units of cord blood are not deemed worth the resources to cryogenically save because they lack stem cells. The cord blood is examined to make sure that it is not contaminated and does not contain any potential diseases. Blood is also tested to know if it has a high-enough level of blood-forming cells. Such inspections help create safeguards for people interested in obtaining cord blood for treatment. Cord blood that does not meet the strict standards for transplant use can be used for research.

The process of collecting cord blood for public cord blood banks is often not possible with twins because they are often born much smaller than other babies in addition to often having less cord blood. Public banks typically do not allow collections from twin births. In contrast, private banks will store cord blood from twins for possible use by the family.

Private cord blood banks are an excellent option in case one of your children becomes sick. If one of your children becomes ill, then having saved their cord blood or cord tissue can boost their immune system or improve bone marrow. Having a childs previously saved cord blood from their umbilical cord improves the likelihood of a successful transplant. The blood fights certain cancers as well as specific blood disorders.

An additional benefit of cord blood banking is that other siblings and close family members can use the blood. Using the stem cells from a sibling can prove useful if one of your children develops a genetic disorder. For example, a person with a genetic disorder such as cystic fibrosis cannot be treated by their own cord blood. Cord blood collected from the siblings of that person can often be used to combat the disorder.

A public cord blood bank follows government regulations to protect the public from harm by maintaining certain set standards. The banks follow a wide range of regulations such as state laws and regulations in combination with U.S. Food and Drug Administration (FDA) regulations. If a collected unit or sample of cord blood does not meet the set standards, it is usually used for research or discarded.

Public cord blood banks allow individuals to obtain cord blood for uses such as stem cell transplants. Cord blood units collected and provided to a public cord blood bank are usually placed on a registry to more easily be matched with patients in need.

Cord blood is stored in a public or private cord blood bank with cryogenic preservation.

Some cord blood banks offer the option to preserve both cord blood and cord tissue to collect different types of cells. If possible, saving both the cord blood and cord tissue can help collect more cells for future use.

Private cord blood banks allow direct family members and approved individuals to access personally stored cord blood. In contrast, public cord blood banks collect donations of blood usually at no cost to the donor. The collections at a public bank are then accessible to members of the public on an as-needed basis for allogeneic transplants.

Private cord blood banks: Private cord blood banks allow people to save their childs cord blood and cord tissue for the future. They can be expensive for the initial setup, and they charge annual fees for cord blood storage. However, the benefits can outweigh the costs for parents with other children who have known illnesses that can be treated using cord blood. This type of banking ensures that a family maintains possession of their cord blood so that it can be used as needed by members of the specific family. The U.S. has over 25 private cord blood banks that families can use. If a family elects to use a private cord bank, then a medical carrier service will retrieve the cord blood from the hospital and transport it to the cord blood bank. The courier service assists in making transport more accessible to a wider range of families and eases the burden felt by new parents by checking off one activity from a new parents busy to-do list.

Public cord blood banks: Cord blood donations to public banks are frequently used for research. The banks also help people to obtain access to cord blood for transplants. Individuals donate their babys cord blood without charge, which provides other people the ability to receive much-needed treatment. Public cord banks located throughout North America allow more people to access these services.

Hybrid cord blood banks: Some banks offer public and private services. These banks store your childs blood for the future and accept cord blood donations for use by the public. Hybrid cord blood banks help people to access cord blood from various areas within the country as well as from the larger international cord blood banking system. Hybrid banks provide improved access to a wider range of available cord blood.

An autologous transplant or stem-cell transplant occurs when healthy stem cells from your body are used to help improve your bone marrow. Bone marrow can be found within your bones, and it helps to create red and white blood cells. An individual with weakened bone marrow faces life-threatening complications. An autologous transplant helps to address these concerns by placing previously removed stem cells back into your body.

The process is common for individuals that need cancer treatment such as chemotherapy. People who need chemotherapy will have some healthy stem cells removed and then undergo chemotherapy. Afterward, the healthy stem cells are replaced to help improve their bone marrow.

An autologous transplant shouldnt be confused with an allogeneic stem cell transplant. The main difference is that an allogeneic stem cell transplant comes from other people while an autologous stem cell transplant comes from yourself.

When researching cord blood banking, its common to have questions along the way. If you intend to give birth, consider the benefits of cord blood banking while speaking with the hospital and cord blood bank to understand the expected process. Ask about possible risks and prices before making a final decision.

Private cord blood banking can be expensive. One reason that cord blood banking has high costs is that its not usually covered by insurance. However, families with histories of certain illnesses have the possibility of getting a portion of the costs offset by insurance. Costs usually include initial storage fees, which are $1,000 or more, in addition to yearly storage fees. The storage fees range between $200 and $300 annually.

Not all hospitals offer cord blood banking procedures. The hospitals that do offer cord blood banking usually do not complete the banking procedure in-house. The hospitals and cord blood banks often work in tandem because the hospitals extract the cord blood from the umbilical cord while cord blood banks store the cord blood. See if the hospital youll be using provides the option of a cord blood procedure. Its common for a courier to transport the cord blood to a specified cord blood banking lab to complete the procedure.

Go here to see the original:
What is Cord Blood Banking? - Benzinga